ProBioGenThe Strasbourg-based biotech company Transgene and the Berlin-based CDMO ProBioGen have entered into a licensing agreement to collaboratively advance the development of individualised cancer vaccines.
By Benff - Own work, CC BY-SA 4.0, https://commons.wikimedia.org/w/index.php?curid=128081038In both, liver fibrosis and resolution of MASH, Novo Nordisk’s GLP1 modulator semaglutide has shown convincing results in the Phase III ESSENCE study suggesting a label extension of the obesity blockbuster.
Innate PharmaFrench Innate Pharma SA announced the appointment of Jonathan Dickinson as the Company’s newChief Executive Officer (CEO) and Chairman of the Executive Board. He succeeds Hervé Brailly, co-founder of the Company, who was interim CEO, during the search process.
© Niclas Jessen Studio/Bracco Imaging SpARadiopharmaceuticals specialist Blue Earth Therapeutics Ltd will use a U$76.5m Series A financing to finance Phase II development of its targeted prostate cancer radiopharmaceuticals Lutetium (177-Lu) rhPSMA-10.1 and Actinium (225-Ac) rhPSMA-10.1.